Aggressive and malignant pituitary tumours: state-of-the-art
Open Access
- 1 November 2018
- journal article
- review article
- Published by Bioscientifica in Endocrine-Related Cancer
- Vol. 25 (11) , R559-R575
Abstract
Pituitary adenomas are unique in multiple ways. They are rarely malignant in terms of metastases; yet, they may be aggressive. Their cancerous potential is defined in a classic oncological way by the ability to metastasise, and therefore, it has been crucial to differentiate this process from aggressive behaviour, characterised as a particularly invasive and/or recurrent behaviour and resistance to common modalities of therapy. Recently, however, important changes have been introduced to the diagnosis and management of aggressive and malignant pituitary tumours including the 4th edition of the World Health Organization (WHO) classification for endocrine tumours (2017) as well as ESE Clinical Guidelines (2018), although an attempt to establish predictive and/or prognostic markers of clinical aggressiveness remains difficult. In this review, we focus on a group of pituitary tumours causing significant problems in clinical practice and requiring multidisciplinary input. We summarise updates in definitions of tumour invasiveness, aggressiveness and malignant transformation, as well as histological classification, and emphasise the new considerations regarding aggressive and malignant potential and its relationship to therapeutic strategies.Keywords
This publication has 98 references indexed in Scilit:
- Survival and Death Strategies in Glioma Cells: Autophagy, Senescence and Apoptosis Triggered by a Single Type of Temozolomide-Induced DNA DamagePLOS ONE, 2013
- Pituitary Carcinoma: Difficult Diagnosis and TreatmentThe Journal of Clinical Endocrinology & Metabolism, 2011
- EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomasJournal of Clinical Investigation, 2011
- HER2/ErbB2 Receptor Signaling in Rat and Human Prolactinoma Cells: Strategy for Targeted Prolactinoma TherapyMolecular Endocrinology, 2011
- Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 1 – molecular pathwaysJournal of Cellular and Molecular Medicine, 2010
- Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 2 – clinical implicationsJournal of Cellular and Molecular Medicine, 2010
- Therapeutic Targeting of the DNA Mismatch Repair PathwayClinical Cancer Research, 2010
- Temozolomide (Temodar®) and capecitabine (Xeloda®) treatment of an aggressive corticotroph pituitary tumorPituitary, 2009
- Metastatic prolactinoma presenting as a cervical spinal cord tumour in multiple endocrine neoplasia type one (MEN‐1)Clinical Endocrinology, 2006
- Crooke's Cell Adenoma of the PituitaryAmerican Journal of Surgical Pathology, 2003